| Bid | 2.81 |
| Market Cap | 147.37M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.76 |
| PE Ratio (ttm) | -3.87 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.2 |
| Volume | 4,428 |
| Avg. Volume (20D) | 32,936 |
| Open | 2.98 |
| Previous Close | 2.89 |
| Day's Range | 2.94 - 3.01 |
| 52-Week Range | 2.76 - 8.96 |
| Beta | undefined |
About NBTX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership ...
Analyst Forecast
According to 1 analyst ratings, the average rating for NBTX stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 307.47% from the latest price.
1 year ago · proactiveinvestors.com
Nanobiotix surges on commercialization deal with J&J's Janssen for cancer therapeuticFrench biotechnology company Nanobiotix has entered into an agreement with J&J's wholly-owned medical research and pharmaceutical arm Janssen to license, co-develop and commercialize a drug to treat h...
1 year ago · proactiveinvestors.com
Nanobiotix stock skyrockets on final negotiations with ‘major' drug maker for its cancer treatmentNanobiotix SA (EPA:NANO) shares soared 250% to $7.11, on volume of more than 29 million shares, Friday after the France-based clinical biotechnology company said it has entered into final contract neg...
